July 25, 2016 08:58 ET Covers Innovus Pharmaceuticals' Upcoming FDA Decision, Robust Portfolio, and Improved Cash Reserves and Financials

REDONDO BEACH, CA--(Marketwired - Jul 25, 2016) -, a leading financial news and information portal offering free real time public company filing alerts, announces the release of an article discussing the current state of affairs and future outlook of Innovus Pharmaceuticals, Inc. (OTC PINK: INNV).

The biotechnology and pharmaceutical industries have significantly underperformed the S&P 500 so far this year -- by 25.7% and 12.6%, respectively -- but there are many opportunities for investors willing to assume some risk. Microcap biotech firms are largely under-the-radar of institutional investors, which means that individual investors have an opportunity to capitalize on discounted opportunities and generate alpha for their portfolios.

Innovus Pharmaceuticals is an emerging pharmaceutical company that delivers safe, innovative, and effective over-the-counter medicine and consumer care products designed to improve men and women's health, respiratory disease, and vitality. In addition to completing the acquisition of Beyond Human™, the company may be on the verge of an FDA approval of its FlutiCare™, Fluticasone Propionate Abbreviated New Drug Application (ANDA) for over-the-counter allergy relief medication.

This article takes a look at the company's upcoming FDA decision, robust commercial portfolio, and improved cash reserves and financial condition. To read, click on the following link or cut and paste the URL into your browser:

For more information, visit the company's website at or download our free Company Analysis.


Founded in 2004, provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.


Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit:

Contact Information